Nadine Mallak , Burcak Yilmaz , Catherine Meyer , Celeste Winters , Anna Mench , Abhinav K. Jha , Vikas Prasad , Erik Mittra
{"title":"神经内分泌肿瘤的血清疗法：最新情况和新兴技术","authors":"Nadine Mallak , Burcak Yilmaz , Catherine Meyer , Celeste Winters , Anna Mench , Abhinav K. Jha , Vikas Prasad , Erik Mittra","doi":"10.1016/j.currproblcancer.2024.101129","DOIUrl":null,"url":null,"abstract":"<div><p>Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies\",\"authors\":\"Nadine Mallak , Burcak Yilmaz , Catherine Meyer , Celeste Winters , Anna Mench , Abhinav K. Jha , Vikas Prasad , Erik Mittra\",\"doi\":\"10.1016/j.currproblcancer.2024.101129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.</p></div>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0147027224000709\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147027224000709","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
摘要
体生长激素受体（SSTR）靶向成像和分化良好的神经内分泌肿瘤（NET）治疗方面的进步彻底改变了这些肿瘤的治疗方法。这篇综合综述深入探讨了当前的实践，讨论了各种经 FDA 批准的 SSTR 激动剂 PET 示踪剂和预测性成像生物标志物的使用，并详细阐述了 Lu177-DOTATATE 肽受体放射性核素疗法（PRRT），包括不断发展的治疗后成像实践、PRRT 再治疗以及剂量测定在优化患者治疗中的潜在作用。未来方向部分重点介绍了正在进行的 PET 成像放射性核素研究、α粒子疗法的未来前景以及联合治疗策略。
Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies
Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
